Oral dabigatran etexilate versus enoxaparin for venous thromboembolism prevention after total hip arthroplasty: Pooled analysis of two phase 3 randomized trials

Bengt I. Eriksson, Ola E. Dahl, Nadia Rosencher, Andreas Clemens, Stefan Hantel, Martin Feuring, Jörg Kreuzer, Michael Huo, Richard J. Friedman

Research output: Contribution to journalArticle

16 Scopus citations

Abstract

Background: Two phase 3 trials compared 28-35 days of treatment with oral dabigatran 220 mg or 150 mg (RE-NOVATE) or 220 mg (RE-NOVATE II) once daily with subcutaneous enoxaparin 40 mg once daily for prevention of venous thromboembolism (VTE) after elective total hip arthroplasty. Methods: This prespecified pooled analysis compared the outcomes for the dabigatran 220 mg dose with enoxaparin, which included 4,374 patients. Total VTE (venographic and symptomatic) plus all-cause mortality (primary efficacy), major VTE (proximal deep vein thrombosis [DVT] or non-fatal pulmonary embolism) plus VTE-related death, and bleeding events were evaluated. Efficacy analysis was based on the modified intention-to-treat (ITT) population and safety analysis was based on all treated patients. The common risk difference (RD) for dabigatran versus enoxaparin was estimated using a fixed effects model. Results: Total VTE and all-cause mortality occurred in 6.8 % (114/1,672) and 7.7 % (129/1,682) (RD:-0.8 %, 95 % confidence interval [CI] -2.6 to 0.9) for dabigatran and enoxaparin, respectively. Major VTE plus VTE-related mortality occurred in 2.7 % (46/1,714) and 4.0 % (69/1,711) (RD: -1.4 %, 95 % CI -2.6 to -0.2) of patients receiving dabigatran 220 mg and enoxaparin, respectively. Major bleeding occurred in 1.7 % (37/2,156) and 1.3 % (27/2,157) (RD: 0.5 %, 95 % CI -0.2 to 1.2), for dabigatran and enoxaparin respectively. Conclusions: Extended prophylaxis with oral dabigatran 220 mg once daily was as effective as enoxaparin 40 mg once daily in reducing the risk of total VTE and all-cause mortality after total hip arthroplasty, with a similar bleeding profile. The clinically relevant outcome of major VTE and VTE-related death was significantly reduced with dabigatran versus enoxaparin. Trial registration: NCT00657150and NCT00168818

Original languageEnglish (US)
Article number36
JournalThrombosis Journal
Volume13
Issue number1
DOIs
StatePublished - Nov 17 2015

Keywords

  • Arthroplasty
  • Bleeding
  • Dabigatran
  • Deep vein thrombosis
  • Enoxaparin
  • Mortality
  • Prophylaxis
  • Pulmonary embolism
  • Venous thromboembolism

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Oral dabigatran etexilate versus enoxaparin for venous thromboembolism prevention after total hip arthroplasty: Pooled analysis of two phase 3 randomized trials'. Together they form a unique fingerprint.

  • Cite this